scholarly journals A Case of Heterotopic Ossification in Papillary Renal Cell Carcinoma Type 2

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Facundo Davaro ◽  
Elizabeth Davaro ◽  
Amna Qureshi ◽  
Lindsay Lombardo
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Heterotopic Ossification ◽  
Renal Cell ◽  
Specific Immunotherapy ◽  
Papillary Renal Cell Carcinoma ◽  
Young Female ◽  
Prognostic Implications ◽  
Papillary Type

Renal cell carcinoma (RCC) is associated with a variety of different histopathologic subtypes in which each subtype may be further subclassified. These entities carry with them unique prognoses and necessitate treatment with specific immunotherapy agents should advanced disease be uncovered. Meanwhile, aberrant physiologic processes may lead to unique histologic findings within these subtypes, further complicating management and prognostication. Heterotopic ossification within RCC is one of these rare occurrences and was once thought to have favorable prognostic implications. We report a case of a young female with papillary type 2 RCC with heterotopic ossification.

scholarly journals A type 2 papillary renal cell carcinoma presenting as an intracystic necrotic lesion: A case report

2013 ◽  
Vol 1 (2) ◽  
pp. 318-320 ◽  
Author(s):  
ZHENYU FU ◽  
LIGUO SUN ◽  
YUHUA HUANG ◽  
JIE ZHANG ◽  
ZICHAO ZHANG ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Case Report ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Necrotic Lesion

scholarly journals An Antioxidant Response Phenotype Shared between Hereditary and Sporadic Type 2 Papillary Renal Cell Carcinoma

Cancer Cell ◽  
2011 ◽  
Vol 20 (4) ◽  
pp. 511-523 ◽  
Author(s):  
Aikseng Ooi ◽  
Jing-Chii Wong ◽  
David Petillo ◽  
Douglas Roossien ◽  
Victoria Perrier-Trudova ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Antioxidant Response ◽  
Response Phenotype

scholarly journals Combined Papillary Renal Cell Carcinoma with Neuroendocrine Differentiation and Mucinous Tubular and Spindle Cell Carcinoma

2018 ◽  
Vol 2018 ◽  
pp. 1-5
Author(s):  
Gang Wang ◽  
Ren Yuan ◽  
Tracy Tucker ◽  
Allan B. Gates ◽  
Christopher D. Bellamy ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Spindle Cell ◽  
Neuroendocrine Differentiation ◽  
Papillary Renal Cell Carcinoma ◽  
Spindle Cell Carcinoma ◽  
Unique Case ◽  
Primary Neoplasm

A unique case of combined papillary renal cell carcinoma (PRCC) and mucinous tubular and spindle cell carcinoma (MTSCC) presenting in a man aged 67 years is reported. The two separate components were distinct on morphological, immunohistochemical (IHC), and genetic grounds, while type 2 PRCC predominated. Three years after the initial diagnosis, the PRCC component metastasized to the lungs where it morphologically mimicked a pulmonary neuroendocrine tumor. Retrospectively focal neuroendocrine differentiation was demonstrated by IHC in the PRCC component of the primary neoplasm.

scholarly journals Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2

2019 ◽  
Vol 37 (10) ◽  
pp. 721-726 ◽  
Author(s):  
Emily C.L. Wong ◽  
Richard Di Lena ◽  
Rodney H. Breau ◽  
Frederic Pouliot ◽  
Antonio Finelli ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Prognostic Predictor

scholarly journals Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma

2009 ◽  
Vol 15 (4) ◽  
pp. 1162-1169 ◽  
Author(s):  
Tobias Klatte ◽  
Allan J. Pantuck ◽  
Jonathan W. Said ◽  
David B. Seligson ◽  
Nagesh P. Rao ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Tumor Profiling

A case of type 2 papillary renal cell carcinoma

2019 ◽  
Vol 58 (3) ◽  
pp. 120-125
Author(s):  
Mai FUNAKOSHI ◽  
Misa ISHIHARA ◽  
Yukari INOUE ◽  
Rie SHIMIZU ◽  
Minoru NISHIDA ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma

A Patient With Newly Diagnosed Metastatic Type 2 Papillary Renal Cell Carcinoma

ONCOLOGY ◽  
2015 ◽  
pp. 880-886
Author(s):  
Maria Bourlon ◽  
Monica Meneses-Medina ◽  
Sara Vasquez-Manjarrez ◽  
Francisco Bustamante-Romano ◽  
Adriana Gallegos-Garza ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Newly Diagnosed

Gene expression profiling identifies two distinct papillary renal cell carcinoma (RCC) subgroups of contrasting prognosis

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4503-4503
Author(s):  
B. T. Teh ◽  
X. J. Yang ◽  
M. Tan ◽  
H. L. Kim ◽  
W. Stadler ◽  
...  
Keyword(s):  
Gene Expression ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Comparative Genomic ◽  
Low Grade ◽  
Class 1

4503 Background: Despite the moderate incidence of papillary renal cell carcinoma (PRCC), there is a disproportionately limited understanding of its underlying genetic programs. There is no effective therapy for metastatic PRCC, and patients are often excluded from kidney cancer trials. A morphological classification of PRCC into Type 1 and Type 2 tumors has been recently proposed, but its biological relevance remains uncertain. Methods: We studied the gene expression profiles of 34 cases of PRCC using Affymetrix HGU133 Plus 2.0 arrays (54,675 probe sets) using both unsupervised and supervised analysis. Comparative genomic microarray analysis (CGMA) was used to infer cytogenetic aberrations, and pathways were ranked with a curated database. Expression of selected genes was validated by immunohistochemistry in 34 samples, with 15 independent tumors. Results: We identified two highly distinct molecular PRCC subclasses with morphologic correlation. The first class, with excellent survival, corresponded to three histological subtypes: Type 1, low-grade Type 2 and mixed Type 1/low-grade Type 2 tumors. The second class, with poor survival, corresponded to high-grade Type 2 tumors (n = 11). Dysregulation of G1/S and G2/M checkpoint genes were found in Class 1 and Class 2 tumors respectively, alongside characteristic chromosomal aberrations. We identified a 7-transcript predictor that classified samples on cross-validation with 97% accuracy. Immunohistochemistry confirmed high expression of cytokeratin 7 in Class 1 tumors, and of topoisomerase IIα in Class 2 tumors. Conclusions: We report two molecular subclasses of PRCC, which are biologically and clinically distinct, which may be readily distinguished in a clinical setting. This may also have therapeutic implications. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document